# Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients

> **NCT01489566** · PHASE3 · UNKNOWN · sponsor: **Shenzhen Kangzhe Pharmaceutical Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Hepatocellular,Carcinoma

## Interventions

- **DRUG:** Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )
- **DRUG:** the placebo ,chemotherapy(mitomycin, and Fluorouracil )

## Key facts

- **NCT ID:** NCT01489566
- **Lead sponsor:** Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-08
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2011-12-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01489566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01489566, "Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01489566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*